The preferred source of arginine for high-output nitric oxide synthesis in blood vessels

被引:29
作者
Xie, LJ
Hattori, Y
Tume, N
Gross, SS
机构
[1] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY USA
[2] Cornell Univ, Weill Med Coll, Program Biochem & Struct Biol, New York, NY USA
[3] Dokkyo Univ, Sch Med, Mibu, Tochigi 32102, Japan
关键词
D O I
10.1016/S0146-0005(00)80054-3
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
L-arginine is the substrate for nitric oxide (NO) production by each of the 3 NO synthase (NOS) isoforms encoded by the mammalian genome. Despite the pivotal roles of NO in mammalian physiology and pathophysiology, the source of arginine for NO synthesis is not clearly defined. In this context, it is notable that cell types that do not have a complete urea cycle often possess the urea cycle enzymes argininosuccinate synthase and argininosuccinate lyase; together, these enzymes confer the ability to regenerate arginine from the NOS product, L-citrulline. Herein, the authors summarize evidence to support the view that argininosuccinate synthase and argininosuccinate lyase function in an arginine-citrulline cycle, providing a ready source of arginine for high-output NO synthesis. The arginine-citrulline cycle is induced in vascular cells by the same cytokines that trigger iNOS expression and provides the preferred source of substrate for NO production. Evidence suggests that argininosuccinate synthase activity is rate-limiting to high- output NO synthesis and, hence, represents a novel target for the treatment of pathophysiological conditions arising from NO overproduction. Copyright (C) 2000 by W.B. Saunders Company.
引用
收藏
页码:42 / 45
页数:4
相关论文
共 35 条
[1]   SUBSTRATE-DEPENDENT REGULATION OF INTRACELLULAR AMINO-ACID-CONCENTRATIONS IN CULTURED BOVINE AORTIC ENDOTHELIAL-CELLS [J].
BAYDOUN, AR ;
EMERY, PW ;
PEARSON, JD ;
MANN, GE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 173 (03) :940-948
[2]   Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease [J].
Böger, RH ;
Bode-Böger, SM ;
Thiele, W ;
Creutzig, A ;
Alexander, K ;
Fröhlich, JC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (05) :1336-1344
[3]   Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells [J].
Bogle, RG ;
Baydoun, AR ;
Pearson, JD ;
Mann, GE .
JOURNAL OF PHYSIOLOGY-LONDON, 1996, 490 (01) :229-241
[4]   Secondary endothelial dysfunction: Hypertension and heart failure [J].
Boulanger, CM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (01) :39-49
[5]   Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris [J].
Ceremuzynski, L ;
Chamiec, T ;
HerbaczynskaCedro, K .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (03) :331-&
[6]  
CHEUNG CW, 1989, J BIOL CHEM, V264, P4038
[7]  
Closs EI, 1999, METHOD ENZYMOL, V301, P78
[8]  
Divino JC, 1997, NEPHROL DIAL TRANSPL, V12, P2339
[9]   Endothelial dysfunction in human disease [J].
Drexler, H ;
Hornig, B .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (01) :51-60
[10]  
Durante W, 1996, P ASSOC AM PHYSICIAN, V108, P356